<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4040AD39-D5FD-45F6-8F39-A54A72D20D39"><gtr:id>4040AD39-D5FD-45F6-8F39-A54A72D20D39</gtr:id><gtr:name>International AIDS Society (IAS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B1AA7BC-AAC4-4FEE-B36F-15AE12508773"><gtr:id>7B1AA7BC-AAC4-4FEE-B36F-15AE12508773</gtr:id><gtr:name>The Sainsbury Family Charitable Trusts</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A861D5B4-C006-49D3-8DF9-5C184B00E4AC"><gtr:id>A861D5B4-C006-49D3-8DF9-5C184B00E4AC</gtr:id><gtr:name>Kenyan Institute for Medical Research (KEMRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9"><gtr:id>B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9</gtr:id><gtr:name>Moi University</gtr:name><gtr:address><gtr:line1>P.O. Box 1125</gtr:line1><gtr:line2>30100</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4040AD39-D5FD-45F6-8F39-A54A72D20D39"><gtr:id>4040AD39-D5FD-45F6-8F39-A54A72D20D39</gtr:id><gtr:name>International AIDS Society (IAS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B1AA7BC-AAC4-4FEE-B36F-15AE12508773"><gtr:id>7B1AA7BC-AAC4-4FEE-B36F-15AE12508773</gtr:id><gtr:name>The Sainsbury Family Charitable Trusts</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A861D5B4-C006-49D3-8DF9-5C184B00E4AC"><gtr:id>A861D5B4-C006-49D3-8DF9-5C184B00E4AC</gtr:id><gtr:name>Kenyan Institute for Medical Research (KEMRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9"><gtr:id>B6961CB7-C2D1-4D66-A8E4-43C981AD3CF9</gtr:id><gtr:name>Moi University</gtr:name><gtr:address><gtr:line1>P.O. Box 1125</gtr:line1><gtr:line2>30100</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F7466C87-76C1-402B-8C55-03D1F0DA2B32"><gtr:id>F7466C87-76C1-402B-8C55-03D1F0DA2B32</gtr:id><gtr:firstName>Ali</gtr:firstName><gtr:surname>Judd</gtr:surname><gtr:orcidId>0000-0003-3176-5295</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6DBFBE00-2D87-4FFD-AF04-089A331AA253"><gtr:id>6DBFBE00-2D87-4FFD-AF04-089A331AA253</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:surname>Ford</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F26"><gtr:id>AC916E03-69C9-4802-8F96-FF8129DB960B</gtr:id><gtr:title>Paediatric and adolescent infections</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/26</gtr:grantReference><gtr:abstractText>Infections are a very important reason why children get sick. In many parts of the world, large numbers of children still die from infectious diseases, like HIV, tuberculosis, malaria and blood infections. This programme of research uses different kinds of studies to answer questions about how we can best manage and treat infections in children and young people, both to reduce their chance of dying and being sick for longer, but also to increase their quality of life. This includes studies to work out what are the best drugs to use, thinking not just about controlling infections like HIV or curing infections like tuberculosis, but also what side-effects the drugs might have or how easy or hard families find it to take different numbers and types of pills every day. Other studies are working out what aspects of living with a long-term infection like HIV have the biggest impact on children and young people?s lives, including how they manage school and friends. The goal is to provide evidence so that national and international guidelines for managing children and young people with infections recommend the best options for them.</gtr:abstractText><gtr:technicalSummary>This integrated programme of complementary randomised trials, cohorts and pharmacovigilance studies aims to address questions about medicines and other interventions relevant to the most frequent and serious infectious diseases affecting children worldwide, in particular HIV, tuberculosis, malaria and sepsis. This is important because infectious diseases still dominate as causes of childhood mortality and morbidity and disproportionately affect children in sub-Saharan Africa. The programme has a large international component in Europe, North and South America, Thailand and Africa, and is at the forefront of both national and international research in paediatric infectious diseases. 
The most appropriate research study designs are used for each specific question, not repeating all studies done in adults but using research in adults to identify where questions may be different or likely have different answers in children. Recognising the relative paucity of research in children, multiple complementary questions are addressed in factorial trials wherever possible to increase the evidence base for clinical management, and add value to the original investment in setting up and running the trial. Substudies investigating aspects such as pharmacokinetics, immunology, virology, and adherence are also included alongside trials wherever possible, as are additional analyses of trial data in an observational framework. High quality additional long-term data can also be collected in trial extensions by linking to cohorts. However, not all questions regarding the optimal management and treatment of HIV-infected children can be answered by randomised trials, because many cannot be framed as an implementable intervention. Data from cohort studies are used to answer these population-level questions of major relevance to children, adolescents and their families.
Our future plans are 
? to continue to address clinically relevant questions in paediatric infectious diseases through appropriate research designs, and 
? to ensure that results are incorporated into national and international management guidelines and policy, and then into clinical practice, including through additional operational research if relevant. 
Several randomised trials in HIV and tuberculosis are funded and in advanced planning phases. Ongoing analyses within cohorts and cohort collaborations led by the group are addressing a wide range of contextual topics that can be generalised to the treatment and care of the wider population of HIV-infected children and young people. A large programme of pharmacovigilance studies continues to provide important long-term safety data to the European Medicines Agency on newly licensed antiretroviral drugs for children.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1145000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>National Institute of Health</gtr:description><gtr:id>892453B5-30AD-4181-9F10-417E07AA8678</gtr:id><gtr:impact>Papers from the CHER trial and PENPACT-1 trial, papers from HPPMCS.</gtr:impact><gtr:outcomeId>aHEqC2f25VC-1</gtr:outcomeId><gtr:partnerContribution>We have collaborated with NIH who funded the CHER trial in South Africa through a CIPRA grant.

NIH have contributed funding and collaboration on the PENPACT-1 trial</gtr:partnerContribution><gtr:piContribution>Provide scientific input in to all aspects of desgin, analysis and write up of the CHER trial (Prof Diana Gibb and Prof Abdul Babiker).

With Prof Lynne Mofenson at NIAID we have worked on PENPACT-1 trial and cohort collaborations (HPPMCS).</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Institute of Child Health</gtr:description><gtr:id>DD93DDB4-C3FB-49C2-8EE7-22F112E4A93D</gtr:id><gtr:impact>MRC grant secured in 2010. Work ongoing with baseline data presented at international conferences. Involves collaboration, training and capacity building between clinical, laboratory and trial management personnel at Ugandan and Zimbabwean sites and MRC CTU and Institute of Child Health. Site laboratory trained in four colour Immunophenotyping, nucleic acid extraction protocols and quantitative and real time PCRs (on HIV, CMV and EBV), and ELISA assays. Further training will be done on other techniques, in year 2 of the study. Training was done by personnel from both CTU and ICH.</gtr:impact><gtr:outcomeId>hF9JhHSkDp2-1</gtr:outcomeId><gtr:partnerContribution>Training, laboratory capacity building, teaching on PENTA Courses in East and West Europe and across Africa; sharing supervision of PhD Wellcome Trust studentships (Prof. Nigel Klein). Working together on EuroCoord, EPPICC, PENTA and Hepatitis C activities (Dr Claire Thorne). Collaborators and grant holders on NIHR PENTA 16 main study and biomarker substudy</gtr:partnerContribution><gtr:piContribution>Collaborators on an MRC Immunology substudy within ARROW, delegating activities as described under an agreement with ICH, and we take responsibility for the project in accordance with the provisions of the Funder; application for NIHR funding for PENTA 16 immunology substudy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gilead Sciences</gtr:description><gtr:id>CE2C6535-EE56-45E6-8E90-7C3674C7C297</gtr:id><gtr:impact>Gilead provided first-line drugs for the trial, without which there would have been no publications. They also provided specific funding for PMID 18444867, 18839777 and for the current PENTA 17 (SMILE) elvitegravir trial</gtr:impact><gtr:outcomeId>7E6F8B128A4-1</gtr:outcomeId><gtr:partnerContribution>Provided drugs for the trial</gtr:partnerContribution><gtr:piContribution>The research team ran the trial: Gilead contributed drugs and funding for specific substudies.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM SC10 - US019</gtr:department><gtr:description>INSERMSC10- US019.Essais th&amp;eacute;rapeutiques et maladies infectieuses</gtr:description><gtr:id>0CE4EE82-7984-4024-A9DA-266B3A42B5F2</gtr:id><gtr:impact>All PENTA trials</gtr:impact><gtr:outcomeId>545ca01e5761c6.61857192-1</gtr:outcomeId><gtr:partnerContribution>Collaboration on management and co-ordination of PENTA trials</gtr:partnerContribution><gtr:piContribution>Collaboration on management and co-ordination of PENTA trials</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Division of Clinical Pharmacology</gtr:department><gtr:description>University of Cape Town</gtr:description><gtr:id>4DAE9F00-6200-40AD-A411-E086DEBD6238</gtr:id><gtr:impact>Analyses of CHAPAS 3 data are currently in progress</gtr:impact><gtr:outcomeId>MccLbSszTQf-1</gtr:outcomeId><gtr:partnerContribution>Dr Helen McIlleron's team designed, coordinate and analyse pharmacokinetic studies in collaboration with Prof David Burger from Nimejgen. 

Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. Clinical site for PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials</gtr:partnerContribution><gtr:piContribution>MRC CTU coordinates the CHAPAS 3, PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kenyan Institute for Medical Research (KEMRI)</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:description>KEMRI, Kilifi</gtr:description><gtr:id>8B379C6C-8981-4E3F-8A25-ED27121029BF</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management.

REALITY clinical trial grant.</gtr:impact><gtr:outcomeId>56d560d109e815.03326385-1</gtr:outcomeId><gtr:partnerContribution>KEMRI are collaborating on the REALITY trial in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moi University</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:description>Eldoret, Kenya</gtr:description><gtr:id>AE4CAEFA-4281-4A23-9A72-DB47152BE2A3</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management.
Multiple clinical trial grants, including EARNEST and REALITY trials.
Publications reporting the results of these trials which have influenced national, regional and international guidelines.</gtr:impact><gtr:outcomeId>56d561cba1a209.41933997-1</gtr:outcomeId><gtr:partnerContribution>The Eldoret site are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EuroCoord</gtr:description><gtr:id>E508DA2E-5044-4C50-AE7A-2EC512D820F7</gtr:id><gtr:impact>The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infectious Diseases. April: 2011, 273-283.</gtr:impact><gtr:outcomeId>tTizKAqUUDp-1</gtr:outcomeId><gtr:partnerContribution>scientific coordinator 2011-2012 (Work Package 3). data harmonisation</gtr:partnerContribution><gtr:piContribution>scientific lead in writing project proposal; major partner. running paediatric PENTA trials and coordinating EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Society (IAS)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>IAS</gtr:description><gtr:id>D6B928C7-0A47-4A0E-A35C-28427B940229</gtr:id><gtr:impact>Outputs forthcoming</gtr:impact><gtr:outcomeId>56dd7bc0659497.33341507-1</gtr:outcomeId><gtr:partnerContribution>Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study.</gtr:partnerContribution><gtr:piContribution>Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration, hosted at IAS. Also collaboration between UCL and IAS for a global paediatric HIV pharmacovigilance study.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Malawi, Republic of</gtr:country><gtr:department>Malawi-Liverpool Wellcome Trust Clinical Research Programme</gtr:department><gtr:description>MLW, Malawi</gtr:description><gtr:id>FD427817-23F3-4C87-B341-CBD68F7982BF</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management.
Multiple clinical trial grants, including EARNEST and REALITY trials.
Publications reporting the results of these trials which have influenced national, regional and international guidelines.</gtr:impact><gtr:outcomeId>56d56184497e79.40832886-1</gtr:outcomeId><gtr:partnerContribution>MLW are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Radboud University Nijmegen Medical Centre, the Netherlands</gtr:description><gtr:id>6B68030A-FA11-45A3-AAC8-150CD740CA45</gtr:id><gtr:impact>Radbound University has been involved in the analysis and writing up of the pharmacokinetics data from ARROW, PENTA 18 and the CHAPAS trials which has resulted in presentations at international conferences, peer review publications, FDA and EMA approval of drugs and Clinton Foundation and UNITAID dissemination in Africa.</gtr:impact><gtr:outcomeId>eiDfjRLy7oE-1</gtr:outcomeId><gtr:partnerContribution>Long standing nesting of key pharmacokinetic studies within larger trial programmes. Contributed to several PhD studentships (all Dutch), PK data resulted in licensing of new appropriate antiretroviral formulations for children in resource limited settings.</gtr:partnerContribution><gtr:piContribution>The research team at the MRC co-ordinates the ARROW, CHAPAS-1,2,3 and PENTA trials and provides scientific input and analysis of EDCTP funded VITA 1 and 2 trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Public Health and Policy</gtr:department><gtr:description>The London School of Hygiene and Tropical Medicine</gtr:description><gtr:id>7F50CDB9-4973-4B2E-BEDB-ECF4846645CB</gtr:id><gtr:impact>3 Social Scientists trained in Africa; publications and presentations at major conferences on qualitative work in ARROW and BREATHER (PENTA 11)</gtr:impact><gtr:outcomeId>FZUGmEuRpgc-1</gtr:outcomeId><gtr:partnerContribution>intensive training in areas of social science adding to collaborations in the African centres (ARROW and PENTA 16). provision of a forum for young people in the ARROW trial to contribute to knowledge about living with HIV infection in Africa</gtr:partnerContribution><gtr:piContribution>coordination and facilitation of the Young Lives substudy in the ARROW trial, qualatative substudy of PENTA 16 (UK, Uganda and US) and input in to AALPHI.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SGUL</gtr:description><gtr:id>F740B643-76F8-45C0-AB89-DFD8997F1530</gtr:id><gtr:impact>Multi-disciplinary - clinical, health economics, laboratory</gtr:impact><gtr:outcomeId>56df0fc0e6f7e8.60332567-1</gtr:outcomeId><gtr:partnerContribution>SGUL - Chief Investigator and Trial Physician; PERUKI, Universities of Oxford/Bristol /UCL ICH- design and analysis of laboratory studies; University of Southampton Health Economics</gtr:partnerContribution><gtr:piContribution>design and conduct of study protocol.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Sainsbury Family Charitable Trusts</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Monument Trust</gtr:department><gtr:description>Monument Trust</gtr:description><gtr:id>2BC00F01-09EF-4EDE-8471-A7A71FA89874</gtr:id><gtr:impact>The Monument Trust funds the pharmacokinetic teams at 2 of the Ugandan trial centres for ARROW and CHAPAS trials. Some second-line children from ARROW are co-enroled in CHAPAS-2.

AALPHI study started recruiting in Q3 2012.</gtr:impact><gtr:outcomeId>bPwUtuuFYeV-1</gtr:outcomeId><gtr:partnerContribution>funding. The Monument Trust also contribute to I-Base publications which CTU staff have input in to.</gtr:partnerContribution><gtr:piContribution>MRC CTU co-ordinates the CHAPAS-2 trial and the AALPHI study</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>Janssen Pharmaceutica</gtr:description><gtr:id>DECF0766-F4FA-430C-8CFE-B0B928829691</gtr:id><gtr:impact>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand. Antiviral Therapy, in press</gtr:impact><gtr:outcomeId>56dd7d866c3773.65904351-1</gtr:outcomeId><gtr:partnerContribution>We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency.</gtr:partnerContribution><gtr:piContribution>We coordinate the EPPICC pharmacovigilance project which provides long-term safety of paediatric HIV drugs to Janssen/ European Medicines Agency.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zimbabwe</gtr:collaboratingOrganisation><gtr:country>Zimbabwe, Republic of</gtr:country><gtr:department>University of Zimbabwe Clinical Research Centre (UZCRC)</gtr:department><gtr:description>UZCRC, Zimbabwe</gtr:description><gtr:id>36192045-EF0C-4E02-8737-FF9DC04EA381</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management.
Multiple clinical trial grants, including DART, ARROW, EARNEST and REALITY trials.
Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines.</gtr:impact><gtr:outcomeId>56d56056bd4f92.34532247-1</gtr:outcomeId><gtr:partnerContribution>UZCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Padova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EPPICC (European Paediatric and Pregnancy HIV Cohort Collaboration)</gtr:description><gtr:id>861CB3EC-A68E-4F26-952B-C13D063FA1CD</gtr:id><gtr:impact>Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009,23:597-604.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Fosamprenavir use in children in the European Union. A report to the European Medicines Agency (EMA), August 2009 (and repeated August 2010). London: MRC Clinical Trials Unit.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS. 2011;25:2279-2287.</gtr:impact><gtr:outcomeId>mnfF9mvvWAa-1</gtr:outcomeId><gtr:partnerContribution>We are leading a new collaborative project (EPPICC infants) for this network, and the network has provided us with data to make the project feasible. The network also contributes epidemiological and clinical expertise to the project.</gtr:partnerContribution><gtr:piContribution>We co-lead this network of paediatric observational HIV cohorts along with the Institute for Child Health. We have co-written the strategic plan for this network for the next 5 year period and have contributed to the EuroCoord bid which has secured funding for this network for the next 5 years.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>JCRC, Uganda</gtr:description><gtr:id>9A99FC78-A8A2-450F-98C4-FAB934C2425E</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory management.
Multiple clinical trial grants, including DART, ARROW, CHAPAS-3, EARNEST and REALITY trials.
Multiple publications reporting the results of these trials which have influenced national, regional and international guidelines.</gtr:impact><gtr:outcomeId>56d56003815396.02870998-1</gtr:outcomeId><gtr:partnerContribution>JCRC are collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and recruiting and managing patients as a key trial site in multiple trials over the last decade.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the treatment and management of adult, adolescent and paediatric HIV infection, providing scientific leadership and expertise in clinical trial design, management and analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gilead</gtr:description><gtr:id>61CE618F-20E8-4E31-B3E1-0C33FC740166</gtr:id><gtr:impact>Final protocol; fpfv planned Q2 2016; clinical, virology, immunology, pharmacokinetics</gtr:impact><gtr:outcomeId>56df11ea241617.17175794-1</gtr:outcomeId><gtr:partnerContribution>Review of protocol; provision of free drug</gtr:partnerContribution><gtr:piContribution>Design and conduct of trial protocol</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Harvard University</gtr:description><gtr:id>A5B53C72-6606-4E81-BCD5-950A369452E3</gtr:id><gtr:impact>Outputs are being generated and are forthcoming.</gtr:impact><gtr:outcomeId>56dd7aaa6bea04.50096056-1</gtr:outcomeId><gtr:partnerContribution>Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration.</gtr:partnerContribution><gtr:piContribution>Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CHIVA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C55CD5F3-8D2A-46EA-88FC-C94C739BE984</gtr:id><gtr:impact>Twice yearly contribution of lay text on the CHIPS study to the CHIVA Newsletter; yearly presentation of key findings from the CHIPS and AALPHI studies at the CHIVA national conference. Updating on results and ongoing PENTA trials

Improved reporting of patients to CHIPS, and general understanding of the CHIPS data and its importance. Recruitment of patients into PENTA trials</gtr:impact><gtr:outcomeId>UiRSqiT5Mbj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stand at International AIDS Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78B539A0-6B23-4701-BCD5-78CD5B064995</gtr:id><gtr:impact>We had a stand at the International AIDS Conference in Durban, distributing outputs from our HIV studies including policy briefs, graphic novels, films and video case studies and other training materials.</gtr:impact><gtr:outcomeId>58a6d804a209a8.44476897</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of BREATHER (PENTA 16) qualitative results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>72E75334-D65E-4914-AB55-95ECAA69BBA7</gtr:id><gtr:impact>Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team. &amp;quot;But it's my story&amp;quot;: exploring the experience and effect of telling children how they have acquired HIV; 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.</gtr:impact><gtr:outcomeId>56e15dda8ca141.04556187</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://penta-id.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>London Specialised Commissioning Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C9E85682-81B8-4180-A6B0-DE7FA844E557</gtr:id><gtr:impact>Annual production of a newsletter (annual report) and slide set which presents CHIPS data in lay language. Presentation of data at twice yearly London HIV Consortium meetings

CHIPS data are now used as the basis for commissioning paediatric HIV services across England, and are being developed to measure quality of services within new designation schemes.</gtr:impact><gtr:outcomeId>NUaMBtmzJVX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival Workshop on Getting Results Faster for Patients</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>87319DBD-DCC7-4FA9-989E-FACDECF704CB</gtr:id><gtr:impact>As part of the Medical Research Council (MRC) Festival of Medical Research, the MRC Clinical Trials Unit at University College London (MRC CTU at UCL) held a half-day workshop exploring how the Unit is working to get faster results and impact from clinical trials. We invited patient representatives involved in our studies, and patient groups who are interested in clinical trials. 30 people from 20 patient groups and various trials attended the workshop, along with around 20 members of MRC CTU at UCL staff.</gtr:impact><gtr:outcomeId>58a6d74c082cf7.91069999</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/news/2016/getting_results_faster_workshop_report_010816</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of qualitative work in BREATHER (PENTA 16 ) in the UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D10CED9-66B5-4C02-8854-E07290ADA210</gtr:id><gtr:impact>Bernays S, Seeley J, Paparini S, Rhodes T and the BREATHER trial teams 'I was like, oh my God, what happens if it doesn't work'?: young people living with HIV, clinical trial participation, and the truth economy accepted for presentation at BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148).</gtr:impact><gtr:outcomeId>56e15f01093131.73726327</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://penta-id.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BREATHER (PENTA 16) results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8E3C4BDB-DECA-4236-BE08-7304709D8FE0</gtr:id><gtr:impact>Presentation of the results of the trial at a major scientific conference. Butler K on behalf of the BREATHER trial team: ART with weekends off is non-inferior to continuous ART in young people on EFV+2 NRTI. CROI 2015, Seattle, USA, Feb 23 -26 2015. Oral presentation abstract 38LB.</gtr:impact><gtr:outcomeId>56e15d386d3881.02983810</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://penta-id.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BREATHER briefing paper</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A1869F3-39A0-4EBA-987F-D1A143C68E53</gtr:id><gtr:impact>We produced a briefing paper on the BREATHER trial results.</gtr:impact><gtr:outcomeId>58a6e72ebab284.15424197</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/breather_briefing_paper</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lablite training briefing paper</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>41456523-E66B-41C1-8F23-A9B499A088AE</gtr:id><gtr:impact>We produced a briefing paper summarising the training approach used within Lablite. This briefing paper was distributed at the International AIDS Conference in Durban.</gtr:impact><gtr:outcomeId>58a6e820b08186.87870857</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of BREATHER and ARROW qualitative work</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>911390F2-CD79-4EB0-83B6-492F92812E20</gtr:id><gtr:impact>Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams 'I am scared of getting caught up in my lie': challenges to self-reported adherence for young people living with HIV; accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)</gtr:impact><gtr:outcomeId>56e15ead0057c3.84560702</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://penta-id.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of further results of BREATHER (PENTA 16) qualitative work</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA418539-9E23-4E7D-9275-CFCB13A8289A</gtr:id><gtr:impact>Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team. Young people, clinical trials and 'the HIV experience': What can similarities across time and place tell us about growing up with HIV? 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.</gtr:impact><gtr:outcomeId>56e15e3a536d35.65625569</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://penta-id.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1618051</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PENTA Foundation, EPPICC grant</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>PENTA Foundation</gtr:fundingOrg><gtr:id>5A118470-78CB-4155-A206-F5FE5CB54361</gtr:id><gtr:outcomeId>56dd9f058c1fa6.58797051</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>314606</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Fellowship Helen Payne (Immunology substudies in CHER Trial)</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>579E4E09-8158-4054-B27E-072527826516</gtr:id><gtr:outcomeId>QwUfDbB41pQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3711258</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Protection Research Unit, Blood Borne and Sexually Transmitted Infections</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>C6334D47-5F8B-4C65-AC20-F8A0FB9DE0DF</gtr:id><gtr:outcomeId>56dd9e785a1cc0.62920928</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205907</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Training Fellowship - Felicity Fitzgerald</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9EB77D42-9628-405B-BB2C-A1A290E411DD</gtr:id><gtr:outcomeId>T6qqdR6LjgQ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46842</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>CIPHER Cohort Collaborative Projects ($ 142964; 2014 - 2015)</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>International AIDS Society (IAS)</gtr:fundingOrg><gtr:id>BE48B973-C9A8-487B-9142-9FFBE1E854F0</gtr:id><gtr:outcomeId>58bea6bb04b974.49295896</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2532729</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/88/11</gtr:fundingRef><gtr:id>EAF18EDF-FD41-4B13-9751-9DCBEF581AF6</gtr:id><gtr:outcomeId>56df067a071cb9.66450510</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158075</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Joint Global Health Trial Development Grant (TABS)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P021492/1</gtr:fundingRef><gtr:id>5A568526-67E5-40C5-8152-8E209D9EF453</gtr:id><gtr:outcomeId>58c548b438c302.42116172</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>780000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative HIV Paediatric Study (CHIPS)/Department of Health</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>NHS England</gtr:fundingOrg><gtr:id>878988B8-85F0-4924-BAAB-AE3E3A9E631C</gtr:id><gtr:outcomeId>NMP6s6mw7xy0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>850000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Monument Trust</gtr:department><gtr:description>Adolescents and Adults Living with Perinatal HIV cohort (AALPHI)/ Monument Trust (Sainsbury Family)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>The Sainsbury Family Charitable Trusts</gtr:fundingOrg><gtr:id>5D6F2B92-B77F-454A-997A-A1EF08B3FA52</gtr:id><gtr:outcomeId>K4GH5bCyJqw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3217996</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A randomized controlled trial of shorter course treatment for uncomplicated minimal childhood tuberculosis (SHINE)</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8C0AC5FA-63EA-4D78-901F-A93130A65FCB</gtr:id><gtr:outcomeId>nkQTM2TMiLg</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>813361</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant (REALITY immunology substudy)</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P022251/1</gtr:fundingRef><gtr:id>4038EA82-2963-4507-AEC4-52090B21DCCE</gtr:id><gtr:outcomeId>58c547c1b820f6.88657515</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3986746</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A8E15357-667D-4E91-B5CC-48AFCBE4DA02</gtr:id><gtr:outcomeId>NyLSsPjZd1q1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6614624</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ViiV: investigator sponsored study</gtr:description><gtr:end>2021-05-02</gtr:end><gtr:fundingOrg>Viiv Healthcare</gtr:fundingOrg><gtr:id>A2256EAD-A4F4-4227-9EB2-20C8FA57B2F3</gtr:id><gtr:outcomeId>56df06e6dee1c3.73565308</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>371694</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Fellowship Julia Kenny (CHAPAS 3 Trial &amp;amp; Substudies)</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F82343C9-437A-4093-A2E8-66ECF2C3403D</gtr:id><gtr:outcomeId>Cq7d9Nu3bJS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lablite training handbook adopted by Ugandan Ministry of Health</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>33403765-9EE2-4437-A2CD-88C17FB84604</gtr:id><gtr:outcomeId>56dee7c15e2eb1.09024901</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of CIPHER Steering Committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>697C4F1C-6CE5-43C3-B85A-1DC011566FF1</gtr:id><gtr:outcomeId>56dd9cc62490a7.31042957</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, Paediatric/ Obstetric Subgroup of the HIV Clinical Reference Group, NHS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7FB51B4-9062-4801-ADF4-8A556D3D2AC3</gtr:id><gtr:outcomeId>56dd9d1b10e847.36058702</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in NIH paediatric HIV guidelines, 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the use of antiretroviral agents in pediatric HIV infection</gtr:guidelineTitle><gtr:id>37D561AC-9D20-4EF1-B32C-97CCC15B3515</gtr:id><gtr:outcomeId>56dd9b4c311038.72853980</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children</gtr:guidelineTitle><gtr:id>9E206636-3A98-4143-AACA-37F1637A9F91</gtr:id><gtr:impact>The new WHO guidelines recommend that rapid fluid resuscitation is not used for children with 1 or 2 signs of shock, following the results of the FEAST trial. However, they still recommend (more conservative) fluid resuscitation for children with all three signs of shock.
FEAST found that rapid fluid resuscitation was associated with excess mortality for children with any definition of shock. The new guidelines are progress, but do not completely accord with the FEAST recommendations.</gtr:impact><gtr:outcomeId>56d8696cb42953.04813542</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/204463/1/9789241510219_eng.pdf?ua=1</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>ODYSSEY (Once daily dolutegravir in young people vs standard therapy) - A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART. FPFV due April 2016. Funding from EU, PENTA Foundation, ViiV, INSERM.</gtr:description><gtr:id>E34DB280-A630-416A-B2BF-3D3302EA3659</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>545ca1e6649a88.47166020</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ODYSSEY - PENTA 20</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://penta-id.org</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Raltegravir is an integrase inhibitor licenced for the treatment of HIV infection. In the REALITY trial we are testing using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (&amp;gt;5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduces early mortality on treatment.</gtr:description><gtr:id>230894B1-898D-4D3E-957B-C00C1ECE32B2</gtr:id><gtr:impact>None.</gtr:impact><gtr:outcomeId>56d5c1470665c6.22920869</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Raltegravir</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Plumpynut is a nutritional supplement made from peanuts, and including specific multi-vitamins and multi-minerals. In the REALITY trial we are testing using it as adjunctive therapy for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (&amp;gt;5 years) with severe immunosuppression when they start anti-HIV treatment, to see if it reduces early mortality on treatment.</gtr:description><gtr:id>FC59BBAC-9A69-4CC4-B0AE-46353E7729D6</gtr:id><gtr:impact>None.</gtr:impact><gtr:outcomeId>56d5c1ad1c8937.42192173</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Plumpynut</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community Acquired Pneumonia (CAP): a randomIsed controlled Trial (CAP-IT). Funded by NIHR HTA. Recruitment started Q1 2017. Collaboration with PERUKI, SGUL, Universities of Bristol, Southampton, Oxford.</gtr:description><gtr:id>100B13BE-6CC8-4095-B755-C68727D18455</gtr:id><gtr:impact>Feasibility study completed. Pilot study will include validation of saliva swabs against nasopharyngeal swabs for identification of S.pneumoniae and identification of changes in antibiotic resistance.</gtr:impact><gtr:outcomeId>56df0ba76b1999.43571633</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CAP-IT - amoxicillin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>HTA 13/88/11</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.</gtr:description><gtr:id>875D0478-F8D1-4F52-AB7E-E31A21C77473</gtr:id><gtr:impact>First patient expected Q2 2016</gtr:impact><gtr:outcomeId>56d7328e90baa2.61054467</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>elvitegravir</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.penta-id.org</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>In the REALITY trial we are testing a &amp;quot;bundle&amp;quot; of drugs as enhanced prophylaxis for 12 weeks (in addition to standard triple combination therapy) in HIV-infected adults, adolescents and older children (&amp;gt;5 years) with severe immunosuppression when they start anti-HIV treatment, to see if the bundle reduces early mortality on treatment. The bundle contains isoniazid (anti-tuberculosis), fluconazole (anti-cryptococcus), azithromycin (anti-bacterial infections) and albendazole (anti-helminths).</gtr:description><gtr:id>D1E0D218-E19B-411D-8F8E-4DCDEEE6E337</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>56d5c24020e591.48417904</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Enhanced opportunistic infection prophylaxis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The AALPHI database contains clinical, neurocognitive and psychsocial data on 300 vertically HIV-infected young people and a comparison group of 100 HIV negative controls in the UK.</gtr:description><gtr:id>27F89731-C9CA-422D-B283-D1CAA56062FD</gtr:id><gtr:impact>Recruitment is in progress. This work is expected to significantly contribute to the evidence base on how to treat young people with vertical HIV in the future.</gtr:impact><gtr:outcomeId>56dd97313c9559.44404618</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>AALPHI database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Establishment of collaborative database containing clinical data on HIV-infected children in globally, representing all regions</gtr:description><gtr:id>CA9B5D9A-74BB-41A0-9D2A-983540372695</gtr:id><gtr:impact>Under development</gtr:impact><gtr:outcomeId>56dd80ed9fd034.33538019</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CIPHER database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Establishment of collaborative database containing clinical data on HIV-infected children in the UK/Ireland</gtr:description><gtr:id>EEEB1EB0-972E-4A4F-90E5-3D4FAB19809F</gtr:id><gtr:impact>Many publications written by us, and by collaborators, over the years - see URL below. Citations in international clinical guidelines.</gtr:impact><gtr:outcomeId>56dd816f63cc95.85941934</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CHIPS database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.chipscohort.ac.uk/default.asp</gtr:url></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Establishment of collaborative database containing clinical data on HIV-infected children in Europe</gtr:description><gtr:id>AF4D0D99-F949-4160-8E25-45309A301873</gtr:id><gtr:impact>Development of database has resulted in collaborative research projects and publications, both within the EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration) group, and in collaboration with other cohort collaborations, such as COHERE and EuroCoord.</gtr:impact><gtr:outcomeId>56dd9657a1d523.40908383</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EPPICC database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://penta-id.org/hiv/eppicc-studies.html</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BC69C71F-49A5-4D17-9FBF-6B9191F9A142</gtr:id><gtr:title>Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16a0e2cac032025257ed2f44c93f19d"><gtr:id>d16a0e2cac032025257ed2f44c93f19d</gtr:id><gtr:otherNames>Crook AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>571df16641cce6.70595667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F82DBB7-16A6-4327-A7F6-4A9F4BFFD9DC</gtr:id><gtr:title>Opportunities for improving the efficiency of paediatric HIV treatment programmes.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f10685ed46e33a0e6d19ab20a253cb8"><gtr:id>0f10685ed46e33a0e6d19ab20a253cb8</gtr:id><gtr:otherNames>Revill PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d559a00f8c17.92877270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCA07071-D24A-4456-B52C-38F7B46A264E</gtr:id><gtr:title>Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a85a4081d2554a9d6391e21802e5fdd"><gtr:id>3a85a4081d2554a9d6391e21802e5fdd</gtr:id><gtr:otherNames>Bwakura-Dangarembizi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>56d559a045d0c1.19615274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB16E10D-5CF1-4145-930D-40AACD0CEC9A</gtr:id><gtr:title>The expanding role of co-trimoxazole in developing countries</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ed9d3740013c3bd76003ce2f4299970"><gtr:id>6ed9d3740013c3bd76003ce2f4299970</gtr:id><gtr:otherNames>Church J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56e18849ebf735.58896511</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EF9AB5F-D1D9-4DAD-9E48-5EEBA9FD14A4</gtr:id><gtr:title>Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca9f5ba3d0dbec482d341d3eb3929910"><gtr:id>ca9f5ba3d0dbec482d341d3eb3929910</gtr:id><gtr:otherNames>Musoke P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d559a1265f68.49079784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>515ADC12-2CDD-487B-A281-094E1480225F</gtr:id><gtr:title>Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24458c08d0d487d652c1a2bfe83e59bc"><gtr:id>24458c08d0d487d652c1a2bfe83e59bc</gtr:id><gtr:otherNames>Kekitiinwa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>5a9eab11a5f216.97235875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>683A49F3-3297-47D7-81E1-0F705E5D9839</gtr:id><gtr:title>BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f68718866bd42d1e2f68cc4c9090b3a"><gtr:id>9f68718866bd42d1e2f68cc4c9090b3a</gtr:id><gtr:otherNames>Butler K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>58b3fb2002a3a1.56577058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F15C3F4-AF68-4049-B8E4-578CB1CD6C5D</gtr:id><gtr:title>Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13334b7a921ccad568d04c73b5e50814"><gtr:id>13334b7a921ccad568d04c73b5e50814</gtr:id><gtr:otherNames>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a995f3d932fb3.48984048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F46F612-EEF7-41BA-A71B-E3356BFEB288</gtr:id><gtr:title>Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24458c08d0d487d652c1a2bfe83e59bc"><gtr:id>24458c08d0d487d652c1a2bfe83e59bc</gtr:id><gtr:otherNames>Kekitiinwa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>586bb8416a8fd2.37614327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4E79C13-73A9-414B-9A6F-159C1D79DF70</gtr:id><gtr:title>Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da9d74f94d2e484bd71b0b6e6e2f9d6"><gtr:id>3da9d74f94d2e484bd71b0b6e6e2f9d6</gtr:id><gtr:otherNames>Bamford A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56df17445774c3.78178585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA21B215-69EC-49D5-81FF-BED3E9172D92</gtr:id><gtr:title>Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76796f3ea56696c7017727d7ffcb6d46"><gtr:id>76796f3ea56696c7017727d7ffcb6d46</gtr:id><gtr:otherNames>Bienczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c031b5339432.09686152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9652BC4-7C1B-41DE-AB9B-856047416E8F</gtr:id><gtr:title>Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13334b7a921ccad568d04c73b5e50814"><gtr:id>13334b7a921ccad568d04c73b5e50814</gtr:id><gtr:otherNames>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>56dd791ebe6371.00177841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8E76191-1F15-49C4-9270-05E1D62B9D3B</gtr:id><gtr:title>The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a33fa6051a8ca7b043ffc187a316bff"><gtr:id>4a33fa6051a8ca7b043ffc187a316bff</gtr:id><gtr:otherNames>Ford D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>56e04f6c9b07e8.66952668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB2AF880-3B56-470E-967A-965424505BA8</gtr:id><gtr:title>Once vs twice-daily abacavir and lamivudine in African children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3d78c5672e7bdca46d5ced1d2d76a0"><gtr:id>0e3d78c5672e7bdca46d5ced1d2d76a0</gtr:id><gtr:otherNames>Musiime V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>571df166af9fa2.17060269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62F2C692-565A-42C8-982E-8638F55D5517</gtr:id><gtr:title>Immunodeficiency at the start of combination antiretroviral therapy: steady improvement or step changes?</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffadb08aae12c5867ce7c13b7fc78833"><gtr:id>ffadb08aae12c5867ce7c13b7fc78833</gtr:id><gtr:otherNames>Olson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e187a9be4f57.63099362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ED0DF03-FD4F-4052-A927-B6FC6375BBAB</gtr:id><gtr:title>Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6101149f297e83932ea1ed2f0d0b052"><gtr:id>d6101149f297e83932ea1ed2f0d0b052</gtr:id><gtr:otherNames>BREATHER (PENTA 16) Trial Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>58b3fadc600271.27380233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8541E39B-EC28-43E5-994E-E1838F3E037D</gtr:id><gtr:title>Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d105be070a3190725488c10ec8251c9c"><gtr:id>d105be070a3190725488c10ec8251c9c</gtr:id><gtr:otherNames>Lange CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e180dd90df14.92232052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>749DEA16-5496-4B4E-88EB-112A99D6BAB2</gtr:id><gtr:title>Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 transitioning to adult care: moving on up.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>58be9e2c946006.42787691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE7C49AB-B5EA-43A3-9577-BFD3DF9AF93A</gtr:id><gtr:title>Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa18d244c5f3fd031a697c9b076f35a7"><gtr:id>fa18d244c5f3fd031a697c9b076f35a7</gtr:id><gtr:otherNames>Dirajlal-Fargo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>5a9ea83e0d3285.36769235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C20CEB2D-0B74-4AE6-BA8B-1E6BCAC01A97</gtr:id><gtr:title>Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76796f3ea56696c7017727d7ffcb6d46"><gtr:id>76796f3ea56696c7017727d7ffcb6d46</gtr:id><gtr:otherNames>Bienczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c02f9f9298e6.17940153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4849AE2C-9C46-46B2-AAE5-A1F185FA2354</gtr:id><gtr:title>Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58b995a8c41a31.28533385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1B726CF-DDB0-4956-AA31-CE0819B1DC31</gtr:id><gtr:title>Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0598db42888b59ad2869e007dd04eb5c"><gtr:id>0598db42888b59ad2869e007dd04eb5c</gtr:id><gtr:otherNames>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a995ec4273400.92683834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B1E1D13-DA17-4AF6-80D9-C0F9907E505E</gtr:id><gtr:title>Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cb02c210ad075574973e08568831ee2"><gtr:id>7cb02c210ad075574973e08568831ee2</gtr:id><gtr:otherNames>Schomaker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58bea1768c11a3.10191740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B74C14B4-4AE6-470D-8BE2-5A977BEACD33</gtr:id><gtr:title>Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7517295f45ff7151cd20ed611a3bf8f0"><gtr:id>7517295f45ff7151cd20ed611a3bf8f0</gtr:id><gtr:otherNames>Cambiano V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56e04f6d2ea199.80388407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>756F9281-70F7-44F4-BFCA-74EB30267387</gtr:id><gtr:title>Sustainable HIV treatment in Africa through viral-load-informed differentiated care.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0347029edd25544ce2768050ff9b3d5c"><gtr:id>0347029edd25544ce2768050ff9b3d5c</gtr:id><gtr:otherNames>Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56e04f6d113c65.97158504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D056C8C-3CF7-415D-9EDD-7BD3D378B98F</gtr:id><gtr:title>Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2d5ac94974cfb9a4cd49c119ea70ed"><gtr:id>6d2d5ac94974cfb9a4cd49c119ea70ed</gtr:id><gtr:otherNames>Ngo-Giang-Huong N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>58bea17740d025.98895460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7EF76E8-687C-43E3-A094-EBEAF2045CE5</gtr:id><gtr:title>Treating hepatitis C virus in children: time for a new paradigm.</gtr:title><gtr:parentPublicationTitle>Journal of virus eradication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3642291d4f808eb3d4339525a1dfe49f"><gtr:id>3642291d4f808eb3d4339525a1dfe49f</gtr:id><gtr:otherNames>Thorne C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2055-6640</gtr:issn><gtr:outcomeId>56e185e205b728.35016746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>257E1F6E-C5C7-4307-84D3-16AC795C9FE9</gtr:id><gtr:title>HIV treatment cascades: how can all countries reach the UNAIDS 90-90-90 target?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c33c2520f44f104bc153ec98ba14cf47"><gtr:id>c33c2520f44f104bc153ec98ba14cf47</gtr:id><gtr:otherNames>Hill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56e1854ad004c8.43129632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FB78100-1B21-4655-AF4C-589D23896096</gtr:id><gtr:title>Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>58b992b5a6ed75.06800380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17BE65DC-A552-435A-8520-56CEB3E9B836</gtr:id><gtr:title>Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19d67076663ff089ee9205dce5758d2c"><gtr:id>19d67076663ff089ee9205dce5758d2c</gtr:id><gtr:otherNames>Szubert AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a2fd79131afb9.12899526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42E17E0F-6ECC-4AC5-A68C-7F58F46FD4AD</gtr:id><gtr:title>Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36bf6d0791aab24f9ae44c8acd439a0b"><gtr:id>36bf6d0791aab24f9ae44c8acd439a0b</gtr:id><gtr:otherNames>Lewis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a3cddc0de4590.79770642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2F3FB42-B918-4736-8EE8-252109421FD9</gtr:id><gtr:title>HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56d7317c7c0947.14045608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A4FD6B2-DED9-420E-8906-B502CBA7DF09</gtr:id><gtr:title>Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe867304a2afe0453c28f658bc7e187c"><gtr:id>fe867304a2afe0453c28f658bc7e187c</gtr:id><gtr:otherNames>Prendergast AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>586bb841913cb2.99823674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63911ABF-10A1-42AD-A87C-91ACF9123F94</gtr:id><gtr:title>Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.</gtr:title><gtr:parentPublicationTitle>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b529eb279a274670249945a9366a160e"><gtr:id>b529eb279a274670249945a9366a160e</gtr:id><gtr:otherNames>Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1025-496X</gtr:issn><gtr:outcomeId>58be9e2bde1a21.34368264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0385D09-6E59-4A51-916A-33DD14594D21</gtr:id><gtr:title>Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58be9e2c5ac793.52610352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFBE643B-6AC6-415E-8723-A6F2623F8205</gtr:id><gtr:title>Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a22cdedac4bd986c28181b428e1b1c2d"><gtr:id>a22cdedac4bd986c28181b428e1b1c2d</gtr:id><gtr:otherNames>Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58bea177a0e9c2.62598168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B0823DE-2195-4951-8559-8A6CF5B2CD70</gtr:id><gtr:title>Incidence of pneumococcal and varicella disease in HIV-infected children and adolescents in the United Kingdom and Ireland, 1996-2011.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8b7109cdc0d70aad0062ab59d94c5"><gtr:id>38a8b7109cdc0d70aad0062ab59d94c5</gtr:id><gtr:otherNames>Payne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>56e180dd1e77b6.87115333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>710C296E-92ED-4E1A-902C-E15A67E156B6</gtr:id><gtr:title>Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.</gtr:title><gtr:parentPublicationTitle>European journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0598db42888b59ad2869e007dd04eb5c"><gtr:id>0598db42888b59ad2869e007dd04eb5c</gtr:id><gtr:otherNames>European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-6970</gtr:issn><gtr:outcomeId>58bea177752c16.12281117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BB43146-9564-45D9-BB9A-2FB8CC08D8C0</gtr:id><gtr:title>Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54610c8251e23c0ee233e6ab5bb11538"><gtr:id>54610c8251e23c0ee233e6ab5bb11538</gtr:id><gtr:otherNames>Childs T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56e180dd429d54.61083132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB3D3CB9-338B-44BA-994B-006F6061393B</gtr:id><gtr:title>Episodic medication adherence in adolescents and young adults with perinatally acquired HIV: a within-participants approach.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a424e78b67219fa6bb113e3ebe84cb5"><gtr:id>0a424e78b67219fa6bb113e3ebe84cb5</gtr:id><gtr:otherNames>Hawkins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>56dd791edf0247.79681117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A595ED4-B30A-4679-BAAC-D4F4AD667435</gtr:id><gtr:title>The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Journal of virus eradication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/954aab51d29e99d1ee06674120432ab5"><gtr:id>954aab51d29e99d1ee06674120432ab5</gtr:id><gtr:otherNames>Palma P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2055-6640</gtr:issn><gtr:outcomeId>56e1865fa57877.23228978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB8B70AF-2541-4F88-B37C-D4890EBC37DE</gtr:id><gtr:title>Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi.</gtr:title><gtr:parentPublicationTitle>Value in health regional issues</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb5e5ae22d0f6f9f1f3476e13377f88"><gtr:id>cbb5e5ae22d0f6f9f1f3476e13377f88</gtr:id><gtr:otherNames>Chiwaula LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2212-1099</gtr:issn><gtr:outcomeId>58c030c93b1049.76218602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62F6D814-DD7C-44E8-84AA-702854F4D72A</gtr:id><gtr:title>Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/559080c7a81aa84b3ce0eb096b40b5c9"><gtr:id>559080c7a81aa84b3ce0eb096b40b5c9</gtr:id><gtr:otherNames>Le Prevost M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>5a9e9ffc2d9809.09460832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFA7E075-3214-4192-8108-EC41229399C1</gtr:id><gtr:title>Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0680f6bdbad4df4144b0b7a3cc48f871"><gtr:id>0680f6bdbad4df4144b0b7a3cc48f871</gtr:id><gtr:otherNames>Pansa P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>5a3cddc1c567c9.68442407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D2FFD45-0316-4E37-9EDA-95F5E0EAA146</gtr:id><gtr:title>Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f17748497205539169a47b40c5f8f264"><gtr:id>f17748497205539169a47b40c5f8f264</gtr:id><gtr:otherNames>Mulenga V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56d559a275c010.93441394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A16D9D62-4E5A-45FA-9B53-00ACD528BF1D</gtr:id><gtr:title>HCV treatment in children and young adults with HIV/HCV co-infection in Europe.</gtr:title><gtr:parentPublicationTitle>Journal of virus eradication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2055-6640</gtr:issn><gtr:outcomeId>56e1843a188b51.04325615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9B2087-D988-453C-85AD-BE8BDA8068A9</gtr:id><gtr:title>A growth reference for mid upper arm circumference for age among school age children and adolescents, and validation for mortality: growth curve construction and longitudinal cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6237127fcb860b48414d3ba9b3d42963"><gtr:id>6237127fcb860b48414d3ba9b3d42963</gtr:id><gtr:otherNames>Mramba L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a3cddc0bdced1.92008541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18ACE518-9362-4BA3-B140-64DE0E022657</gtr:id><gtr:title>When information does not suffice: young people living with HIV and communication about ART adherence in the clinic.</gtr:title><gtr:parentPublicationTitle>Vulnerable children and youth studies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea5bab1a0df6482aef59fd5760d2af"><gtr:id>93ea5bab1a0df6482aef59fd5760d2af</gtr:id><gtr:otherNames>Bernays S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-0128</gtr:issn><gtr:outcomeId>56df165c844ed1.36791652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E45269CC-7B17-41CC-B382-CD0EBBE4F2B5</gtr:id><gtr:title>Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4c7ca53e46aa178bdcf825f4f9b9acb"><gtr:id>e4c7ca53e46aa178bdcf825f4f9b9acb</gtr:id><gtr:otherNames>Mpoya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56d559a1ee4749.29566331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCDCF101-2347-4A38-9BD4-493266009983</gtr:id><gtr:title>Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58bea176c6f475.00727254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>765100C3-DA10-4AB4-8F77-91119D320DF8</gtr:id><gtr:title>Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/877126584f5331a3e389efc46544e6b3"><gtr:id>877126584f5331a3e389efc46544e6b3</gtr:id><gtr:otherNames>Abongomera G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>5a9ea7898eda81.37057825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5D716E2-FFAC-466E-ABE1-86933A800AC0</gtr:id><gtr:title>Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/424bdd3b00309f1c2c4977254eea48ef"><gtr:id>424bdd3b00309f1c2c4977254eea48ef</gtr:id><gtr:otherNames>Tierrablanca LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>5a981c3e5954a7.43329249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC01D50C-436D-47DD-B4E7-C76DB65B0FE8</gtr:id><gtr:title>Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women (Option B+) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a33fa6051a8ca7b043ffc187a316bff"><gtr:id>4a33fa6051a8ca7b043ffc187a316bff</gtr:id><gtr:otherNames>Ford D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c01b0836ac22.17498878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABFB2871-4333-4316-8F57-FF50AAC4C6CF</gtr:id><gtr:title>Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/877126584f5331a3e389efc46544e6b3"><gtr:id>877126584f5331a3e389efc46544e6b3</gtr:id><gtr:otherNames>Abongomera G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>56e04f6dad3132.13834766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A50EF87-0AF3-473B-A020-BDCC3CCB0A88</gtr:id><gtr:title>CHAPAS-3 fills the gap</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7794dee4d58e924f18d3a1116d00417d"><gtr:id>7794dee4d58e924f18d3a1116d00417d</gtr:id><gtr:otherNames>Moultrie H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56e16624351d00.23115124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C473D2E5-3CC3-4D6A-B41F-64CFE5258EED</gtr:id><gtr:title>Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ea5bab1a0df6482aef59fd5760d2af"><gtr:id>93ea5bab1a0df6482aef59fd5760d2af</gtr:id><gtr:otherNames>Bernays S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58b3fa1df2db23.50555876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA42953-D0C7-4723-84D4-F8CCCF03EDD8</gtr:id><gtr:title>Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/384b04922ff8fd8e644428e3c4cd9d4b"><gtr:id>384b04922ff8fd8e644428e3c4cd9d4b</gtr:id><gtr:otherNames>George EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56d559a178c608.95289198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A2E8E7A-CC60-4FC6-B147-9EBDE105F1A8</gtr:id><gtr:title>Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8b7109cdc0d70aad0062ab59d94c5"><gtr:id>38a8b7109cdc0d70aad0062ab59d94c5</gtr:id><gtr:otherNames>Payne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56e180dd71f0f1.78523252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A360187B-ED26-464B-82E1-0B38E3A8F90C</gtr:id><gtr:title>Who Gets Severe Gynecomastia Among HIV-infected Children in the United Kingdom and Ireland?</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4eddb0cc7499466ab802a8e6d83d23b"><gtr:id>f4eddb0cc7499466ab802a8e6d83d23b</gtr:id><gtr:otherNames>Kenny J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>58bea17644d309.49100631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA05C071-6D49-440E-8946-00FCC0446676</gtr:id><gtr:title>Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/910027350b165def0c0d633dd224f403"><gtr:id>910027350b165def0c0d633dd224f403</gtr:id><gtr:otherNames>Nkhata MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>58c01b086d8096.11838523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B9FAA76-7731-455F-8951-09E96C5C2C93</gtr:id><gtr:title>Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd791e9a0657.36891750</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/26</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>